Back to Search
Start Over
Supplementary Methods, Figures 1 - 11, Tables 1 - 6 from hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- PDF file - 738K, ADDITIONAL MATERIALS AND METHODS, FIGURES AND TABLES Fig S1- Immunohistochemical detection of hERG1 protein in GC specimens. Fig S2- hERG1 protein expression in GC primary samples. Figure S3- hERG1b characterization in primary GC. Fig S4- hERG1 protein expression in GC cell lines. Fig S5- hERG1USO protein expression in GC cell lines. Fig S6- Effects of the PI3K/Akt inhibition on VEGF-A secretion in AKG cells under normoxic conditions. Fig S7- Immunohistochemical detection of hERG1 protein in GC specimens. Fig S8- Immunohistochemical detection of hERG1 protein in GC specimens. Fig S9- VEGF-A and hERG1 expression in GC samples. Fig S10. Interaction analyses on OS between hERG1 and other clinical and pathological parameters (Forest Plot). Fig S11- Comparison between herg1a mRNA and hERG1A protein expression in GC samples. Table S1- Antibodies used for IHC experiments described in the main text. Table S2- Primer Sequences. Primers were used for methylation analysis and RQ-PCR. Table S3- Cell lines used in the experiments described in the main text. Table S4- hERG1 expression in AKG cells treated with alpha-hERG1 siRNAs and WAY hERG1 blocker. Table S5- VEGF-A and Kv 1.3 expression in AKG cells treated with alpha-hERG1 siRNAs, WAY hERG1 blocker and alpha-vegf-a siRNA. Table S6- Characteristics of patients excluded and included into the statistical analyses and distributions of clinical and pathological variables after multiple imputation of missing values.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....011758fc31e435475ec105799f7ee3fe